Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm
Portfolio Pulse from
Kuehn Law, PLLC is investigating potential breaches of fiduciary duties by officers and directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX). The investigation focuses on possible self-dealing, and shareholders may be entitled to damages and corporate governance reforms.
February 10, 2025 | 11:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kuehn Law is investigating Syndax Pharmaceuticals for potential breaches of fiduciary duties by its officers and directors, focusing on possible self-dealing. This could lead to shareholder damages and corporate governance reforms.
The investigation by Kuehn Law into potential fiduciary breaches by Syndax Pharmaceuticals' officers and directors could negatively impact the stock price due to legal uncertainties and potential financial liabilities. The focus on self-dealing raises concerns about corporate governance, which may affect investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100